Cover Image

In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Azael Freites‐Martinez, Zoe Apalla, Vincent Sibaud
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Journal of the European Academy of Dermatology and Venereology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash
by: Giovanni Paolino, et al.
Published: (2025)

Dermatologic immune‐related adverse events: It is time for a game change!
by: Davide Fattore, et al.
Published: (2024)

Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients
by: Matilde Iorizzo, et al.
Published: (2025)

Prevention and management of cutaneous immune‐related adverse events: EADV Task Force statement
by: Davide Fattore, et al.
Published: (2025)

Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia
by: Azael Freites‐Martinez, et al.
Published: (2025)

Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study
by: Damien Giacchero, et al.
Published: (2025)

Leg ulcers associated with tyrosine kinase inhibitors of vascular endothelial growth factor receptors
by: Lykimheng Lor, et al.
Published: (2025)

Supportive oncodermatology is the key!
by: E. Parriel, et al.
Published: (2024)

Advanced age and dermoscopic streaks increase the likelihood of a diagnostic upgrade of ambiguous melanocytic tumours after clinicopathological correlation
by: Emmanouil Chousakos, et al.
Published: (2024)

Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa”
by: Fabrizio Martora, et al.
Published: (2024)

Management of folliculitis decalvans: The EADV task force on hair diseases position statement
by: Anna Waśkiel‐Burnat, et al.
Published: (2025)

The immune ensemble behind mogamulizumab‐associated rash
by: Oleg E. Akilov
Published: (2026)

Dermatologic adverse events associated with amivantamab: A multicentre study
by: Vasiliki Nikolaou, et al.
Published: (2026)

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance
by: Kim A. Papp, et al.
Published: (2025)

Management of classic lichen planopilaris: The EADV task force on hair diseases position statement
by: Seyed Morteza Seyed Jafari, et al.
Published: (2026)

Sequelae of epidermal necrolysis: Patients are still in demand years later
by: Audrey Colin, et al.
Published: (2025)

Macrophages and plasmocytoid dendritic cells are recruited to the epidermis during epidermal necrolysis
by: Ines Saizonou, et al.
Published: (2025)

Prevalence and predictors of posttraumatic stress disorder in Stevens Johnson syndrome and toxic epidermal necrolysis
by: T. J. Stewart, et al.
Published: (2025)

Beyond the scoreboard: Coaches' UV‐related skin cancer knowledge in outdoor sports
by: Sven Schneider, et al.
Published: (2024)

Prevalence of risk factors affecting the use of oral JAK inhibitors in hidradenitis suppurativa
by: Ditte Georgina Zhang, et al.
Published: (2025)

Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis
by: Pauline Bataille, et al.
Published: (2024)

BAUSSS biomarker further validated as a key risk staging tool for patients with primary melanoma
by: Anthony J. Dixon, et al.
Published: (2024)

Digital dermoscopy follow‐up for acquired longitudinal melanonychia
by: Elvira Moscarella, et al.
Published: (2025)

Association of dermoscopic signs of regression in melanocytic lesions with immune checkpoint inhibitor response in metastatic melanoma patients
by: Samy Belkaïd, et al.
Published: (2025)

A scoping review of case reports and small case series in Stevens–Johnson syndrome/toxic epidermal necrolysis
by: Mitesh G. Patel, et al.
Published: (2025)

Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large‐scale meta‐analysis in immune‐mediated inflammatory diseases
by: Noémi Ágnes Galajda, et al.
Published: (2025)

TNF inhibitors and cardiovascular risk: Friend or foe?
by: Joel M. Gelfand, et al.
Published: (2024)

Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis
by: N. Á. Galajda, et al.
Published: (2024)

Risk factors for a poor response to propranolol for infantile haemangioma: A prospective study
by: Kaizhi Zhang, et al.
Published: (2025)

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
by: Damien Sanogo, et al.
Published: (2025)

Association of Janus kinase inhibitors with reduced depression in alopecia areata
by: Chih‐Yi Ho, et al.
Published: (2025)

Correspondence to ‘Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis’
by: Shiuan‐Chih Chen, et al.
Published: (2025)

Interpreting the risk of venous thromboembolism with JAK inhibitors in atopic dermatitis
by: Sheng Li, et al.
Published: (2025)

Compassionate use efficacy of the interferon‐beta inhibitor dazukibart in dermatomyositis
by: Ruth Ann Vleugels, et al.
Published: (2026)

Combining an anti‐IL‐4Rα biologic with a JAK1 inhibitor leads to a higher treatment response in resistant atopic dermatitis versus monotherapy alone: A case series
by: A. Ferreirinha, et al.
Published: (2024)

Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
by: Dimitrios Rigopoulos, et al.
Published: (2024)

Scratching the surface: NK‐1 inhibitors for chronic itch—Promise or placebo?
by: Gil Yosipovitch
Published: (2025)

Critical methodological enhancements for JAK inhibitor safety studies in atopic dermatitis
by: Zheying Huang, et al.
Published: (2025)

Melanosis and isolated follicular vitiligo during checkpoint inhibitors for metastatic melanoma
by: Valentine Salvestrini, et al.
Published: (2024)

Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
by: Chaofan Wang, et al.
Published: (2025)